The role of nitric oxide in tissue destruction

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 5, 2001, Pages 831-845

  Abramson, Steven B ^a   Amin, Ashok R ^a   Clancy, Robert M ^a   Attur, Makhundan ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Arthritis; Inflammation; Nitric oxide; Nitric oxide synthase isoforms; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARGININE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN DERIVATIVE; CYTOKINE; GLUCOCORTICOID; INDOMETACIN; ISOENZYME; METHOTREXATE; N(G) METHYLARGININE; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE INHIBITOR; SALICYLATE SODIUM; TETRACYCLINE DERIVATIVE; VASODILATOR AGENT;

ADHESION; ANTIINFLAMMATORY ACTIVITY; BIOSYNTHESIS; BLEEDING; CARTILAGE CELL; CYTOTOXICITY; EDEMA; ENDOTHELIUM CELL; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNITY; IMMUNOREACTIVITY; IMMUNOREGULATION; INFLAMMATION; MICROVASCULATURE; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; VASODILATATION;

EID: 0035696544     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0196     Document Type: Article

References (60)

1. Perspectives series: Nitric oxide and nitric oxide synthases. Inducible nitric oxide synthase: What difference does it make?
2. Perspectives series: Nitric oxide and nitric oxide synthases. Nitric oxide in excitable tissues: Physiological roles and disease
3. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus
4. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: Possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo
5. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients
6. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease
7. Biochemistry of nitric oxide and its redox-activated forms
8. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase
9. Nitric oxide regulates mitochondrial respiration and functions of articular chondrocytes
10. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide
11. The chemistry of peroxynitrite: A product from the reaction of nitric oxide with superoxide
12. Nitrosative stress: Activation of the transcription factor OxyR
13. Acetylcholine prevents intercellular adhesionn molecule I (CD54)-induced focal adhesion complex assembly in endothelial cells via a nitric oxide-cGMP-dependent pathway
14. Outside-in signaling in the chondrocyte. Nitric oxide disrupts fibronectin-induced assembly of a subplasmalemmal actin/Rho A/focal adhesion kinase signaling complex
15. The role of nitric oxide in multiple sclerosis
16. Perspective series: First host/pathogen interactions. Mechanisms of nitric oxide related antimicrobial activity
17. Nitric oxide: An endogenous modulator of leukocyte adhesion
18. The expression and regulation of nitric-oxide synthase in human osteoarthritis-affected chondrocytes: Evidence for up-regulated neuronal nitric oxide synthase
19. Nitric oxide and arthritis
20. Suppression of arthritis by an inhibitor of nitric oxide synthase
21. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease. Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine
22. Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis
23. Modulation of human T cell responses by nitric oxide and its derivative, S-nitrosoglutathione
24. Modulation of autoimmune diseases by nitric oxide
25. Nitric oxide-mediated apoptosis in murine peritoneal macrophages
26. The role of nitrix oxide in articular cartilate damage
27. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms
28. Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human b2 microglobulin transgenic rats
29. Peroxynirite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice
30. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2
31. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity
32. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus
33. Circulating activated endothelial cells in systemic lupus erythematosus: Further evidence for diffuse vasculopathy
34. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level
35. Animal models of arthritis in NOS2-deficient mice
36. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides
37. Nitric oxide production of superficial and deep articular chondrocyte
38. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients
39. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds
40. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1
41. Effects of nitric oxide on matrix metalloproteinase-2 production by rheumatoid synovial cells
42. Nitric oxide attenuates cellular hexose monophosphate shunt response to oxidants in articular chondrocytes and acts to promote oxidant injury
43. Nitric oxide is a mediator of apoptosis in the rheumatoid joint
44. Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases
45. Activation of stress activated protein kinase in osteoarthritic cartilage: Evidence for nitric oxide dependence
46. Functional genomic analysis in arthritis-affected cartilage: Yin-Yang regulation of inflammatory mediators by 5β1 and αvβ3
47. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage
48. NOS/COX cross-talk: Nitric oxide activates COX-1 but inhibits COX-2 derived prostaglandin production
49. Autocrine production of IL-1 by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2 and IL-8
50. Reversal of autocrine and paracrine effects of IL-1 in human arthritis by type II IL-1 receptor: Potential for pharmacological intervention
51. The mode of action of aspirin-like drugs: Effect on inducible nitric oxide synthase
52. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
53. Regulation of nitric oxide and prostaglandin E2 production by CSAIDS (SB203580) in murine macrophages and bovine chondrocytes stimulated with LPS
54. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis
55. Gastrointestinal sparin anti-inflammatory drugs - Effects on ulcerogenic and healing responses
56. Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the ris of complications
57. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding
58. Nitric oxide donating compounds inhibit HCI-induced gastric mucosal lesions mainly via prostaglandin
59. Preventive effect of teprenone on stress-induced gastric mucosal lesions and its relation to gastric mucosal constitutive nitric oxide synthase activity
60. NO-releasing NSAIDs are caspase inhibitors